UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its “LG ...

When urologists convene, they often discuss the newest technologies that can help them better serve their patients. In the case of upper tract urothelial carcinoma (UTUC), an exciting treatment ...

PRINCETON, N.J., April 27, 2025--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty ...

kidney cross section The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC. The American Urological Association (AUA) and Society of Urologic Oncology ...

TEL AVIV, Israel, May 31, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a ...

blood test Since UTUC is frequently understaged, this predictive biomarker may improve management. Preoperative detection of plasma circulating tumor DNA (ctDNA) predicts muscle-invasive and non-organ ...

"Overall, we need to do a better job with biomarkers in this disease…We don’t have a good way to select our patients…There’s a lot of promise, a lot of interest, but we have to prospectively validate ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub ...

The prognostic value of lymph node yield on oncological outcomes after radical nephroureterectomy with lymph node dissection in patients with upper tract urothelial carcinomas is unclear. Careful ...

Cell-free DNA (cfDNA) is one of the important biomarkers of liquid biopsy for many malignant cancers like urothelial bladder cancer. However, the use of cfDNA in upper tract urothelial carcinoma (UTUC ...